New method to detect early-stage cancer identified.

New method to detect early-stage cancer identified.

A new method to detect cancer in its early stages using a targeted MRI contrast agent that binds to proteins has been identified by a team of researchers led.

In their study, published in the journal Science Advances, the authors describe a newly identified biomarker for the detection of liver metastases. With current tests like biopsies, cancer in the liver is often detected in advanced stages, which can limit treatment options and lower overall survival rates. The discovery could have wide-ranging impacts, including more effective diagnosis and precision treatment, and less risk to patients.

Using MRI technology, contrast agents carry the element gadolinium to enhance the images. During her previous work analyzing calcium, Yang decided to test how a metal, like gadolinium, would interact with protein.

The protein wraps around the element and carries it to the site for imaging. Yang’s team found that protein design is much more effective in targeting the signs of disease.

“Currently, it is difficult to see early stages of disease in the liver, even in invasive biopsy,” said Yang. “Diagnostic testing using this contrast agent can not only identify the presence of disease but differentiate the stages of disease with high sensitivity and accuracy. That’s the beauty of this work.”

Science Mission